54 related articles for article (PubMed ID: 37735252)
1. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
[TBL] [Abstract][Full Text] [Related]
3. Cancer/testis antigen CAGE mediates osimertinib resistance in non-small cell lung cancer cells and predicts poor prognosis in patients with pulmonary adenocarcinoma.
Yeon M; Lee H; Yeo J; Jeong MS; Jung HS; Lee H; Shim K; Jo H; Jeon D; Koh J; Jeoung D
Sci Rep; 2023 Sep; 13(1):15748. PubMed ID: 37735252
[TBL] [Abstract][Full Text] [Related]
4. CAGE Binds to Beclin1, Regulates Autophagic Flux and CAGE-Derived Peptide Confers Sensitivity to Anti-cancer Drugs in Non-small Cell Lung Cancer Cells.
Yeon M; Byun J; Kim H; Kim M; Jung HS; Jeon D; Kim Y; Jeoung D
Front Oncol; 2018; 8():599. PubMed ID: 30619741
[TBL] [Abstract][Full Text] [Related]
5. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
6. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
9. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.
Tanaka K; Yu HA; Yang S; Han S; Selcuklu SD; Kim K; Ramani S; Ganesan YT; Moyer A; Sinha S; Xie Y; Ishizawa K; Osmanbeyoglu HU; Lyu Y; Roper N; Guha U; Rudin CM; Kris MG; Hsieh JJ; Cheng EH
Cancer Cell; 2021 Sep; 39(9):1245-1261.e6. PubMed ID: 34388376
[TBL] [Abstract][Full Text] [Related]
10. Adipocytes Promote Breast Cancer Cell Survival and Migration through Autophagy Activation.
Bellanger D; Dziagwa C; Guimaraes C; Pinault M; Dumas JF; Brisson L
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359819
[TBL] [Abstract][Full Text] [Related]
11. Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance.
Mancini M; Thomas QD; Bourdel S; Papon L; Bousquet E; Jalta P; La Monica S; Travert C; Alfieri R; Quantin X; Cañamero M; Maraver A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298655
[TBL] [Abstract][Full Text] [Related]
12. MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription.
Deng L; Vallega KA; Zhang S; Shi P; Sun SY
Neoplasia; 2021 Aug; 23(8):766-774. PubMed ID: 34233230
[TBL] [Abstract][Full Text] [Related]
13. SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.
Xia L; Yang F; Wu X; Li S; Kan C; Zheng H; Wang S
Cancer Cell Int; 2021 Jul; 21(1):337. PubMed ID: 34217295
[TBL] [Abstract][Full Text] [Related]
14. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
15. The CAGE-MiR-181b-5p-S1PR1 Axis Regulates Anticancer Drug Resistance and Autophagy in Gastric Cancer Cells.
Yeon M; Kim Y; Pathak D; Kwon E; Kim DY; Jeong MS; Jung HS; Jeoung D
Front Cell Dev Biol; 2021; 9():666387. PubMed ID: 34113619
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
